Physician profile
Ali Rahimian
NPI 1801805858
$16,601.51
in general payments reported to CMS, 2019-2025
54 companies · $2,385 in 2025
The $2,385 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,718 · 2020: $767 · 2021: $4,002 · 2022: $3,179 · 2023: $2,218 · 2024: $2,333 · 2025: $2,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,935.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,884.82 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,274.15 | 2019-2025 | Fasenra, Airsupra, Farxiga |
| Novo Nordisk INC | $1,668.11 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Biohaven Pharmaceuticals, INC. | $1,275.87 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,108.84 | 2019-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $1,031.91 | 2019-2025 | Mounjaro, Kisunla, Zepbound |
| Pfizer INC. | $516.01 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $479.61 | 2019-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $456.04 | 2023-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $402.67 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $381.28 | 2019-2025 | Jardiance |
| Abbott Laboratories | $327.83 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $323.51 | 2019-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $292.47 | 2019-2023 | Verquvo, Belsomra |
| Antares Pharma, INC. | $281.29 | 2022 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Rahimian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.